# Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer

> **NCT02481830** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 569 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Topotecan
- **DRUG:** Amrubicin

## Key facts

- **NCT ID:** NCT02481830
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-14
- **Primary completion:** 2018-08-17
- **Final completion:** 2022-08-30
- **Target enrollment:** 569 (ACTUAL)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02481830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02481830, "Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT02481830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*